Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit

Result Of Class-Action Suit ‘Extraordinary,’ Court Hears

 
• By Dean Rudge

Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.

Dollar_Gavel
The settlement was granted preliminary approval at the beginning of the year • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin